echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Anesthesia Topics > NEJM: Oral small molecule drug Atogepant for preventive treatment of migraine

    NEJM: Oral small molecule drug Atogepant for preventive treatment of migraine

    • Last Update: 2021-09-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com



    Prevention Atogepant is an oral small molecule CGRP receptor antagonist.


    In this phase III, double-blind study, adult patients with migraine attacks 4-14 days per month participated and were randomized to receive Atogepant treatment or placebo once a day for 12 weeks.


    873 patients participated in the study, including 214 in the 10mg Atogepant treatment group


    After 12 days of treatment, the average monthly migraine attack days in the 10, 30, and 60 mg Atogepant treatment group and the placebo group changed from baseline to -3.


    Studies believe that oral small molecule CGRP inhibitor Atogepant can effectively reduce the number of days of migraine attacks.


    Oral small molecule CGRP inhibitor Atogepant can effectively reduce the number of migraine attacks.


    Original source:

    Jessica Ailani et al.


    Atogepant for the Preventive Treatment of Migraine.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.